Clomifene - Veru Healthcare

Drug Profile

Clomifene - Veru Healthcare

Alternative Names: Cis and trans clomifene - Veru Healthcare; Clomiphene - Veru Healthcare; MSS 722

Latest Information Update: 27 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aspen Park Pharmaceuticals
  • Developer Veru Healthcare
  • Class
  • Mechanism of Action Estrogen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypogonadism; Male infertility

Most Recent Events

  • 27 Jun 2017 Preclinical trials in Male infertility in USA (PO) before June 2017 before June 2017 (Veru Healthcare website, June 2017)
  • 27 Jun 2017 Veru Helathcare announces intention to submit an IND application to US FDA for Hypogonadism and male infertility in 2017 (Veru Healthcare website, June 2017)
  • 27 Jun 2017 Veru Healthcare plans a phase II trial for Hypogonadism and male infertility in USA in 2017 (Veru Healthcare pipeline, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top